Blog
RSS FeedPosted by Michael Wonder on 15 May 2020
Putting a dollar value on life? Governments already do
11 May 2020 - Trade-offs are routine in health policy, and the math and analysis underlying them have been around for ...
Posted by Michael Wonder on 07 May 2020
How are incremental cost effectiveness, contextual considerations, and other benefits viewed in health technology assessment recommendations in the United States?
7 May 2020 - This study reviews ICER assessments to explore the relationship between incremental cost-effectiveness, other benefits, and contextual factors ...
Posted by Michael Wonder on 30 Apr 2020
Using QALYs versus DALYs to measure cost effectiveness: how much does it matter?
30 April 2020 - Quality-adjusted life-years and disability-adjusted life-years are commonly used in cost effectiveness analysis to measure health benefits. Gent ...
Posted by Michael Wonder on 19 Mar 2020
Getting value right: the case for indirect benefits
19 March 2020 - According to the most recent estimates from the Centers for Medicare and Medicaid Services Office of the ...
Posted by Michael Wonder on 02 Feb 2020
ICER finalises 2020 updates to methods and public meeting procedures for value assessment framework
31 January 2020 - Reflecting experience with previous framework, benchmarking with other HTA groups, and input from more than 100 organisations ...
Posted by Michael Wonder on 05 Nov 2019
Obscure model puts a price on good health—and drives down drug costs
4 November 2109 - Concept called QALY places dollar value on the health medicines can restore; ‘starting to influence decision-making’. ...
Posted by Michael Wonder on 17 Oct 2019
Some say a non-profit research group unfairly influences drug prices
16 October 2019 - Have you ever wondered how pharmaceutical companies decide whether that pill you take costs $3 or ...
Posted by Michael Wonder on 15 Oct 2019
Accounting for hope: using ‘mean survival gain’ to price new cancer drugs
14 October 2019 - Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But ...
Posted by Michael Wonder on 09 Sep 2019
As value assessment frameworks evolve, are they finally ready for prime time?
9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...
Posted by Michael Wonder on 09 Sep 2019
Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States
5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...
Posted by Michael Wonder on 15 Aug 2019
ICER's value framework and patient feedback: Q&A with Steve Pearson
15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...
Posted by Michael Wonder on 24 Jun 2019
It’s Pioneer Institute vs. ICER: drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach
24 June 2019 - An influential Boston-based watchdog group uses a “one-size-fits-all” approach to judge a fair price for prescription ...
Posted by Michael Wonder on 20 Jun 2019
Novel approaches to value assessment within the cost-effectiveness framework
20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions ...
Posted by Michael Wonder on 18 Jun 2019
Zolgensma: a remarkable new treatment, an ICER analysis, and a poorly justified price
18 June 2019 - Defects in both sets of alleles in the coding region for the survival motor neuron 1 ...
Posted by Michael Wonder on 15 Jun 2019
New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?
12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...